Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...

Bank of America has a "buy" rating and $100 price target for CRSP stock, which closed at $47.74 on Sept. 16. Intellia Therapeutics is a clinical-stage biotech company developing CRISPR-Cas9 gene ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other ...

What's going on with CRISPR Therapeutics (NASDAQ: CRSP)? The company's shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023 ...

CRISPR Therapeutics (NASDAQ ... now is the best time to buy before it’s too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you ...